Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
250%(5 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(2)
Terminated(5)
Other(1)

Detailed Status

Terminated3
Completed2
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
40.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

completed225%
terminated338%
withdrawn225%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

NCT01981551
completedphase_1

A Trial In Patients With Advanced Cancer And Leukemia

NCT00878189
terminatedphase_1

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

NCT01876251
unknown

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

NCT02955446
terminatedphase_2

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

NCT02109445
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01981551Phase 2

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Completed
NCT00878189Phase 1

A Trial In Patients With Advanced Cancer And Leukemia

Completed
NCT01876251Phase 1

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Terminated
NCT02955446

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

Unknown
NCT02109445Phase 2

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Terminated
NCT02299635Phase 2

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Terminated
NCT02338531Phase 2

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Withdrawn
NCT02462707Phase 1

A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8